Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Cancer research - 15 Aug 2010

Ratner Elena, Lu Lingeng, Boeke Marta, Barnett Rachel, Nallur Sunitha, Chin Lena J, Pelletier Cory, Blitzblau Rachel, Tassi Renata, Paranjape Trupti, Hui Pei, Godwin Andrew K, Yu Herbert, Risch Harvey, Rutherford Thomas, Schwartz Peter, Santin Alessandro, Matloff Ellen, Zelterman Daniel, Slack Frank J, Weidhaas Joanne B

Abstract excerpt

Ovarian cancer (OC) is the single most deadly form of women's cancer, typically presenting as an advanced disease at diagnosis in part due to a lack of known risk factors or genetic markers of risk. The KRAS oncogene and altered levels of the microRNA (miRNA) let-7 are associated with an increased risk of developing solid tumors. In this study, we investigated a hypothesized association between an increased risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Case-Control Studies

Share to Genes, ras

Share to Genetic Markers

Share to Genetic Variation

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 20647319
DOI: 10.1158/0008-5472.CAN-10-0689
PMCID: PMC2923587

Genes

KRAS
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.PMID 20647319Read ↗

The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer.Semantic proximity Read ↗

A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.Semantic proximity Read ↗

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.Semantic proximity Read ↗

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.Semantic proximity Read ↗

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.Semantic proximity Read ↗

Evaluation of the Role of the KRAS Gene Polymorphism LCS6 (rs61764370) in Iraqi Women with Ovarian Cancer.Semantic proximity Read ↗

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.Semantic proximity Read ↗

A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis.Semantic proximity Read ↗

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Semantic proximity Read ↗

KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel.Semantic proximity Read ↗

Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms.Semantic proximity Read ↗

Association of germline variants with KRAS-mutation status in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.